796967-48-1Relevant articles and documents
Diaryl urea compounds with anti-tumor activity as well as preparation method and application of diaryl urea compounds
-
Paragraph 0032; 0033, (2017/08/29)
The invention provides diaryl urea compounds with anti-tumor activity as well as a preparation method and an application of the diaryl urea compounds. A structural formula of the compounds is shown in the specification, wherein R1 represents hydrogen, and R2 represents isopropyl or halogen groups. The compounds have good inhibition activity for VEGFR-2 (vascular endothelial growth factor-2) kinase, and can block VEGFR-2 kinase induced signaling pathways and inhibit tumor cell proliferation and migration by inhibiting activity of VEGFR-2 kinase, so that the compounds can be applied to preparation of anti-tumor drugs. Besides, the preparation method of the compounds has the advantages that raw materials are easily available, reaction conditions are mild, a reaction process is simple to operate and used reagents are cheap.
Discovery of novel anti-angiogenesis agents. Part 7: Multitarget inhibitors of VEGFR-2, TIE-2 and EphB4
Li, Chuansheng,Shan, Yuanyuan,Sun, Ying,Si, Ru,Liang, Liyuan,Pan, Xiaoyan,Wang, Binghe,Zhang, Jie
, p. 506 - 518 (2017/11/14)
Herein, we embarked on a structural optimization campaign aiming at the discovery of second generation anti-angiogenesis agents with our previously reported BPS-7 as lead compound. A library of 27 compounds has been afforded based on the highly conserved ATP-binding pocket of VEGFR-2, Tie-2, and EphB4. Several title compounds exhibited simultaneous inhibitory effects against three angiogenic RTKs. These compounds with a ‘triplet’ inhibition profile have been identified as novel anti-angiogenic and anticancer agents. The representative VDAU11 displayed prominent anti-angiogenic and anticancer potency and could be considered as a candidate for further optimization. These results indicate that N-(pyridin-2-yl)acrylamide could serve as a novel hinge-binding group of triple inhibitors.
COMBINED MODULATION OF IRE1
-
Paragraph 0288, (2016/01/25)
Described herein, inter alia, are combined compositions of an Irel kinase modulating compound and an Irel ribonuc lease modulating compound and methods of using same.